Background

The Cancer Antigen 19-9（CA19-9）CLIA Kit is designed, developed, and produced for the quantitative measurement of human CA19-9 level in serum samples. The assay utilizes a two-site “sandwich” technique with two antibodies that bind to different epitopes of CA19-9. Assay calibrators, controls, or patient serum samples are added directly to a reaction vessel together with acridinium ester magnetic particles and biotinylated anti-CA19-9 polyclonal antibody. The magnetic particles capture the biotin antibody as well as an immunocomplex in the form of “magnetic particles–biotin CA19-9 antibody–streptavidin coated CA19-9–CA19-9 antibody”. Materials bound to the solid beads are held in a magnetic field while unbound materials are washed away. Then, trigger solutions are added to the reaction vessel and light emission is measured with the ECL100 analyzer. The relative light units (RLU) are proportional to the concentration of a CA19-9 in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve and reported in serum CA19-9 concentration.

Selected Literature

​​​​​​​1. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979;5:957-972.
2. Stieber P, Fateh-Moghadam A. Sensible Use of Tumormarkers. Dtsch: Tumormaker und ihrsinnvollerEinsatz. ISBN 3-926725-07-9 dtsch/engl.Juergen Hartmann VerlagMarloffstein-Rathsberg (1993).
​​​​​​​3. Herlyn M, Sears HF, Steplewski Z, et al. Monoclonal antibody detection of a circulating tumor-associated antigen. Presence of antigen in sera of patients with colorectal, gastric and pancreatic carcinoma. J ClinImmunol 1982;2:135- 140.

For in-vitro diagnostic use.